Validation Data Gallery
Tested Applications
| Positive WB detected in | mouse liver tissue, HEK-293 cells, rat liver tissue |
| Positive IP detected in | rat liver tissue |
| Positive IHC detected in | human liver tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:6000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 15 publications below |
| IHC | See 2 publications below |
| IF | See 4 publications below |
| IP | See 1 publications below |
Product Information
16661-1-AP targets UGT2B7 in WB, IHC, IF/ICC, IP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag10121 Product name: Recombinant human UGT2B7 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 25-351 aa of BC030974 Sequence: KVLVWAAEYSHWMNIKTILDELIQRGHEVTVLASSASILFDPNNSSALKIEIYPTSLTKTELENFIMQQIKRWSDLPKDTFWLYFSQVQEIMSIFGDITRKFCKDVVSNKKFMKKVQESRFDVIFADAIFPCSELLAELFNIPFVYSLSFSPGYTFEKHSGGFIFPPSYVPVVMSELTDQMTFMERVKNMIYVLYFDFWFEIFDMKKWDQFYSEVLGRPTTLSETMGKADVWLIRNSWNFQFPYPLLPNVDFVGGLHCKPAKPLPKEMEDFVQSSGENGVVVFSLGSMVSNMTEERANVIASALAQIPQKVLWRFDGNKPDTLGLNT 相同性解析による交差性が予測される生物種 |
| Full Name | UDP glucuronosyltransferase 2 family, polypeptide B7 |
| Calculated molecular weight | 529 aa, 61 kDa |
| Observed molecular weight | 55 kDa |
| GenBank accession number | BC030974 |
| Gene Symbol | UGT2B7 |
| Gene ID (NCBI) | 7364 |
| RRID | AB_2214249 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P16662 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
UDP-glucuronosyltransferase 2B7 (UGT2B7), a member of the UDP-glucuronosyltransferase (UGT) superfamily, mediates phase II biotransformation. During this process, lipophilic substrates undergo glucuronidation conjugation with glucuronic acid, which enhances the aqueous solubility of resultant metabolites and accelerates their elimination via urine or bile (PMID: 10702251; 15231852; 15470161; 15472229). UGT2B7 additionally contributes to the metabolic clearance of mycophenolate, an immunosuppressive pharmaceutical agent (PMID: 15470161).
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for UGT2B7 antibody 16661-1-AP | Download protocol |
| IHC protocol for UGT2B7 antibody 16661-1-AP | Download protocol |
| IP protocol for UGT2B7 antibody 16661-1-AP | Download protocol |
| WB protocol for UGT2B7 antibody 16661-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cell Rep Divergent Expression and Metabolic Functions of Human Glucuronosyltransferases through Alternative Splicing. | ||
Br J Pharmacol UDP-Glucuronosyltransferase (UGT)-Mediated Attenuations of Cytochrome P450 3A4 Activity: UGT Isoform-Dependent Mechanism of Suppression. | ||
Sci Rep Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues. | ||
Sci Rep Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity. | ||
Front Pharmacol Use of a Baculovirus-Mammalian Cell Expression-System for Expression of Drug-Metabolizing Enzymes: Optimization of Infection With a Focus on Cytochrome P450 3A4. |